Reaction: Sacituzumab govitecan to 1 product

Reaction
Sacituzumab govitecan
DB12893
    SN-38
    DBMET01143
    Reaction type
    cleavage
    Direction
    Major circulating metabolite?
    Yes
    Spontaneous?
    No
    Activity
    active
    References
    1. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15;101(4):847-54. doi: 10.1172/JCI915. [Article]
    2. Sahota S, Vahdat LT: Sacituzumab govitecan: an antibody-drug conjugate. Expert Opin Biol Ther. 2017 Aug;17(8):1027-1031. doi: 10.1080/14712598.2017.1331214. Epub 2017 May 22. [Article]
    3. FDA Approved Drug Products: Trodelvy (sacituzumab govitecan-hziy) injection [Link]
    Comments
    Cleavage is thought to be mediated by pH changes, such as those encountered in cell lysosomes and/or the tumour microenvironment.
    Enzymes
    Not Available